We have plenty of substances that can destroy cancer cells in many ways, but the real challenge is making treatments that only target cancer cells to minimize damage to healthy tissues.

4armPEG-DD is a PSMA-targeted drug delivery vehicle designed for enhanced prostate cancer treatment, leveraging several unique features to optimize cancer cell targeting and minimize effects on healthy cells. PEG stands for polyethylene glycol, a versatile polymer already used in pharmaceuticals.

Why 4armPEG-DD Could Be a Game Changer

• Precise Targeting: Designed to bind to PSMA on prostate cancer cells, which is overexpressed in most cases, enhancing treatment focus.
• EPR Effect: Its nano-scale size (about 110 nm) enables it to accumulate in tumor tissues due to the unique vasculature of tumors.
• Controlled Drug Release: The bond with docetaxel breaks within tumor cells, ensuring release primarily where needed.
• Proven Safety: PEG’s established clinical use enhances biocompatibility, potentially speeding up trials due to its safety record.

Source